Get started
Author

Gustavo Peralta-Sánchez

Observed name: Gustavo Javier Peralta-Sánchez
ORCID: 0000-0003-1174-8455
Observed ORCID: 0000-0003-1174-8455
OpenAlex ID: A5041918134
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico
2023 · Samuel Ponce-de-León, Martha Torres, et al. · npj Vaccines · 72
PDF
Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 “Patria” recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico
2024 · Constantino López-Macías, Martha Torres, et al. · Vaccine · 18
Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine
2025 · Constantino López-Macías, Martha Torres, et al. · Science Advances · 6
PDF
Addressing SARS-CoV-2 evolution: neutralization of emerging variants of concern by the AVX/COVID-12 ‘Patria’ vaccine based on HexaPro-S ancestral Wuhan spike or its updated BA.2.75.2 version
2025 · Gregorio Carballo-Uicab, Gabriela Mellado-Sánchez, et al. · Frontiers in Immunology · 3
PDF
Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individuals
2024 · Alejandro Torres-Flores, Luis Alberto Ontiveros-Padilla, et al. · Frontiers in Immunology · 3
Phase II/III Double-Blind Study Evaluating Safety and Immunogenicity of a Single Intramuscular Booster Dose of the Recombinant SARS-CoV-2 Vaccine “Patria” (AVX/COVID-12) Using an Active Newcastle Disease Viral Vector (NDV) during the Omicron Outbreak in Healthy Adults with Elevated Baseline Antibody Titers from Prior COVID-19 and/or SARS-CoV-2 Vaccination
2024 · Constantino López-Macías, Martha Torres, et al. · medRxiv · 2
PDF
Works count: 6
Citation count: 104
H-index: 3
I10-index: 2
Year
Topic
Type